212890-85-2

Basic information

• Product Name: (2S)-4,4-diMethyl-2-PyrrolidineMethanol
• Synonyms: (2S)-4,4-diMethyl-2-PyrrolidineMethanol;2-PyrrolidineMethanol, 4,4-diMethyl-, (2S)-;((S)-4,4-dimethylpyrrolidin-2-yl)methanol
• CAS NO: 212890-85-2
• Molecular Formula: C₇H₁₅NO
• Molecular Weight: 129.2001
• Mol File: 212890-85-2.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2S)-4,4-diMethyl-2-PyrrolidineMethanol(CAS DataBase Reference)
• NIST Chemistry Reference: (2S)-4,4-diMethyl-2-PyrrolidineMethanol(212890-85-2)
• EPA Substance Registry System: (2S)-4,4-diMethyl-2-PyrrolidineMethanol(212890-85-2)

Safety Data

• Hazardous Substances Data: 212890-85-2(Hazardous Substances Data)

Usage

Description

(2S)-4,4-dimethyl-2-pyrrolidinemethanol, also known as DMPM, is a chiral chemical compound with the molecular formula C7H15NO. It is a colorless liquid with a molecular weight of 129.2 g/mol. DMPM is characterized by its pyrrolidine ring structure and two methyl groups, making it a versatile and important chemical in the field of organic synthesis.

Uses

Used in Pharmaceutical Industry:
(2S)-4,4-dimethyl-2-pyrrolidinemethanol is used as a building block for the synthesis of pharmaceuticals and agrochemicals. Its chiral nature makes it a valuable intermediate in the production of optically pure compounds, which are essential for the development of effective and safe drugs.
Used in Chemical Reactions:
(2S)-4,4-dimethyl-2-pyrrolidinemethanol is used as a chiral reagent and a solvent in various chemical reactions. Its unique structure and properties allow it to facilitate and enhance the efficiency of these reactions, making it an important component in the field of organic synthesis.
Used in Organic Synthesis:
(2S)-4,4-dimethyl-2-pyrrolidinemethanol is used as a versatile and important chemical in the field of organic synthesis. Its pyrrolidine ring structure and two methyl groups provide a foundation for the development of new compounds and materials, contributing to advancements in chemistry and related industries.

Upstream product

• 156088-46-9 (5S)-3,3-dimethyl-5-hydroxymethylpyrrolidin-2-one 
• 99208-71-6 (5S)-1-aza-2,2-dimethyl-3-oxa-8-oxo-bicyclo[3.3.0]octane 
• 156088-45-8 (5S)-1-aza-2,2-dimethyl-7,7-dimethyl-3-oxa-8-oxo-bicyclo[3.3.0]octane 
• 1094359-30-4 1-[4,4-dimethyl-1-(toluene-4-sulfonyl)-pyrrolidin-2-ylmethoxy]-2,2,6,6-tetramethyl-piperidine 
• 158392-80-4 1-tert-butyl 2-ethyl (2S)4,4-dimethyl-5-oxopyrrolidine-1,2-dicarboxylate 
• 221637-35-0 (S)-ethyl 4,4-dimethyl-5-oxopyrrolidine-2-carboxylate 
• 144978-35-8 (S)-ethyl N-tert-butoxycarbonylpyroglutamate 

Downstream Products

• 212890-86-3 (S)-(-)-tert-butyl 2-(hydroxymethyl)-4,4-dimethylpyrrolidinecarboxylate 
• 443984-28-9 (S)-(N-benzyloxycarbonyl)-(4,4-dimethylpyrrolidin-2-yl)methan-1-ol 
• 891183-50-9 4,4-dimethyl-L-proline 
• 212890-87-4 (S)-(-)-tert-butyl 2-[(diphenylphosphino)methyl]-4,4-dimethylpyrrolidinecarboxylate 
• 184699-47-6 (S)-(-)-tert-butyl 4,4-dimethyl-2-[((4-methylphenyl)sulfonyloxy)methyl]pyrrolidinecarboxylate 
• 212890-84-1 (S)-2-[(Diphenylphosphanyl)-methyl]-4,4-dimethyl-pyrrolidine 

Relevant articles and documents

TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION

Tetracyclic indole derivatives of formula (I), pharmaceutically acceptable salts and the pharmaceutical compositions thereof are provided, wherein A, A', G, R1, R15, U, V, V, W, W, X, X', Y, Y' are as defined in the invention. Use of these derivatives for treating hepatitis C virus (HCV) infection is also provided.

TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Tetracyclic Indole Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', G, R1, R15, U, V, V', X, X', Y and Y' are as defined herein. The present invention also relates to compositions comprisingat least one Tetracyclic Indole Derivative, and methods of using the Tetracyclic Indole Derivatives for treating or preventing HCV infection in a patient.

FUSED TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES

The present invention discloses novel Fused Tetracyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', G, R1, R15, U, V, V', W, W', X, X', Y and Y' are as defined herein. The present invention also discloses compositions comprising at least one Fused Tetracyclic Heterocycle Compound, and methods of using the Fused Tetracyclic Heterocycle Compounds for treating or preventing HCV infection in a patient.